Exagen Inc.
Index- P/E- EPS (ttm)-2.22 Insider Own2.50% Shs Outstand17.06M Perf Week-18.22%
Market Cap82.62M Forward P/E- EPS next Y-2.09 Insider Trans0.00% Shs Float9.58M Perf Month-31.76%
Income-37.80M PEG- EPS next Q-0.75 Inst Own82.60% Short Float0.47% Perf Quarter4.55%
Sales44.30M P/S1.86 EPS this Y-27.30% Inst Trans-0.60% Short Ratio0.81 Perf Half Y-41.28%
Book/sh3.76 P/B1.34 EPS next Y15.20% ROA-31.40% Target Price14.50 Perf Year-58.88%
Cash/sh4.67 P/C1.08 EPS next 5Y- ROE-47.90% 52W Range4.15 - 14.90 Perf YTD-56.58%
Dividend- P/FCF- EPS past 5Y-2.90% ROI-21.50% 52W High-66.11% Beta-
Dividend %- Quick Ratio9.30 Sales past 5Y32.90% Gross Margin49.60% 52W Low21.69% ATR0.71
Employees219 Current Ratio9.30 Sales Q/Q-29.70% Oper. Margin-79.10% RSI (14)32.35 Volatility13.65% 10.95%
OptionableYes Debt/Eq0.46 EPS Q/Q-106.00% Profit Margin-85.40% Rel Volume1.29 Prev Close5.19
ShortableYes LT Debt/Eq0.45 EarningsAug 04 AMC Payout- Avg Volume56.32K Price5.05
Recom1.50 SMA20-30.58% SMA50-22.98% SMA200-38.01% Volume72,726 Change-2.70%
Aug-05-22Downgrade KeyBanc Capital Markets Overweight → Sector Weight
Oct-15-21Resumed Cowen Outperform $26
Apr-15-21Initiated Canaccord Genuity Buy $25
Nov-10-20Initiated KeyBanc Capital Markets Overweight $32
Oct-08-20Initiated BTIG Research Buy $18
Jun-02-20Resumed Cantor Fitzgerald Overweight $19 → $20
Oct-14-19Initiated William Blair Outperform
Oct-14-19Initiated Cowen Outperform $17
Oct-14-19Initiated Cantor Fitzgerald Overweight $18
Aug-05-22 12:00PM  
Aug-04-22 06:55PM  
Jul-25-22 04:05PM  
Jul-21-22 04:05PM  
Jul-05-22 08:25AM  
Jun-21-22 08:10AM  
Jun-09-22 08:25AM  
May-26-22 04:05PM  
May-16-22 04:05PM  
May-11-22 05:55PM  
May-10-22 10:45AM  
May-03-22 05:15PM  
May-01-22 12:00PM  
Apr-25-22 04:05PM  
Apr-20-22 04:05PM  
Apr-12-22 07:22AM  
Mar-30-22 08:25AM  
Mar-22-22 10:00PM  
Mar-16-22 04:05PM  
Mar-09-22 05:35PM  
Mar-08-22 04:05PM  
Mar-07-22 08:05AM  
Feb-24-22 05:40PM  
Feb-08-22 02:38PM  
Feb-02-22 04:05PM  
Jan-12-22 10:46AM  
Jan-09-22 12:00PM  
Nov-17-21 04:05PM  
Nov-11-21 08:30AM  
Nov-10-21 05:55PM  
Nov-04-21 04:05PM  
Nov-03-21 03:01PM  
Oct-27-21 04:05PM  
Oct-25-21 08:25AM  
Oct-21-21 04:05PM  
Oct-13-21 11:05AM  
Sep-13-21 04:15PM  
Aug-10-21 07:01AM  
Aug-09-21 06:35PM  
Jul-30-21 08:25AM  
Jul-29-21 08:25AM  
Jul-26-21 04:06PM  
Jul-20-21 03:02PM  
Jul-15-21 07:04AM  
Jul-13-21 04:05PM  
Jun-22-21 09:25AM  
Jun-18-21 08:29AM  
May-24-21 04:05PM  
May-12-21 02:30AM  
May-11-21 04:05PM  
May-04-21 04:05PM  
May-03-21 08:25AM  
Apr-27-21 04:05PM  
Apr-16-21 09:45AM  
Mar-29-21 08:25AM  
Mar-25-21 04:15PM  
Mar-22-21 10:01PM  
Mar-16-21 11:30PM  
Mar-12-21 08:33AM  
Mar-09-21 12:30PM  
Mar-03-21 06:06AM  
Mar-02-21 08:00AM  
Feb-22-21 04:05PM  
Feb-15-21 08:58AM  
Feb-03-21 04:05PM  
Jan-22-21 07:22AM  
Jan-21-21 04:05PM  
Jan-10-21 06:00PM  
Jan-05-21 04:05PM  
Jan-04-21 04:05PM  
Dec-11-20 08:35AM  
Nov-18-20 04:05PM  
Nov-16-20 08:25AM  
Nov-13-20 10:19AM  
Nov-10-20 10:01PM  
Nov-09-20 08:25AM  
Nov-02-20 08:25AM  
Oct-27-20 04:05PM  
Oct-21-20 04:05PM  
Oct-12-20 04:05PM  
Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody and associated vasculitis; AVISE Anti-CarP test, which identifies RA patients with severe disease; and AVISE PC4d to measure platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Johnson Wendy S.DirectorSep 03Buy14.021,00014,0201,000Sep 07 08:25 AM